Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Impact of abciximab versus eptifibatide on length of hospital stay for PCIpatients
Autore:
Lage, MJ; Barber, BL; McCollam, PL; Bala, M; Scherer, J;
Indirizzi:
Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA Eli Lilly & CoIndianapolis IN USA 46285 Ctr, Indianapolis, IN 46285 USA Miami Univ, Dept Econ, Oxford, OH 45056 USA Miami Univ Oxford OH USA 45056 iami Univ, Dept Econ, Oxford, OH 45056 USA Centocor Inc, Malvern, PA 19355 USA Centocor Inc Malvern PA USA 19355Centocor Inc, Malvern, PA 19355 USA
Titolo Testata:
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
fascicolo: 3, volume: 53, anno: 2001,
pagine: 296 - 303
SICI:
1522-1946(200107)53:3<296:IOAVEO>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; CORONARY ANGIOPLASTY; ELDERLY PATIENTS; OUTCOMES; REVASCULARIZATION; COMPLICATIONS; PREVENTION; INHIBITION; SEVERITY;
Keywords:
hospital stay; length of stay; multivariate analysis; postprocedural length of stay; retrospective study; sample selection model;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Barber, BL Eli Lilly & Co, Lilly Corp Ctr, Drop Code 1850, Indianapolis, IN 46285 USA Eli Lilly & Co Drop Code 1850 Indianapolis IN USA 46285 285 USA
Citazione:
M.J. Lage et al., "Impact of abciximab versus eptifibatide on length of hospital stay for PCIpatients", CATHET C IN, 53(3), 2001, pp. 296-303

Abstract

The purpose of this study is to compare the profile of percutaneous coronary intervention (PCI) patients who receive abciximab versus eptifibatide, as well as to compare the effect of abciximab versus eptifibatide on hospital length of stay. Retrospective data were obtained from HCIA's Clinical Pathways Database on 5,446 coronary angioplasty patients who were administeredeither abciximab or eptifibatide, Estimation was conducted via a two-stagesample selection model. In the first stage, a probit regression was employed to determine which factors were associated with a higher probability of being administered abciximab versus eptifibatide. In the second stage, a negative binomial model was used to estimate the impact of a wide range of factors (selection of GPIIb/IIIa, patient demographics, insurance provider, health conditions, admission information, and hospital characteristics) on total hospital length of stay, as well as on postprocedural length of stay, After controlling for high-risk indications and other sources of selection bias, results indicate that receipt of abciximab was associated with a significantly shorter length of total hospital stay (0.83 fewer days; P < 0.001) than receipt of eptifibatide. Additionally, receipt of abciximab was found to be associated with a significantly shorter postprocedural hospital length of stay (0.48 fewer days; P = 0.002) compared to receipt of eptitibatide. Results of this study indicate that PCI patients who are administered abciximab versus eptifibatide have a significantly shorter length of hospitalstay (both total and postprocedural). This finding is important since hospital length of stay reflects the occurrence of complications and has been found to be directly related to the resources consumed during in-patient management of patients. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 07:26:44